Guanidinoacetic acid (GAA) is marketed as the smarter cousin of creatine, a precursor your body converts into creatine that supposedly reaches the brain more efficiently. A new randomized trial from Texas A&M finally put that pitch to a human test. The headline finding is a real but patchy reaction-time improvement. Most of the cognitive tests showed nothing.
What Is GAA, and Why Is It Hyped?
GAA is the direct metabolic precursor to creatine. The study's background section notes that earlier work reported GAA can raise brain creatine content more effectively than standard creatine monohydrate (CrM). That claim is the basis of the brain-booster pitch. But higher brain creatine on a scan doesn't automatically mean sharper thinking, and the authors say outright that the effects on cognitive function are unclear. This trial was designed to start answering that.
How the Study Was Run
The research team, led by Richard Kreider's Exercise & Sport Nutrition Lab at Texas A&M, ran a double-blind, randomized, counterbalanced trial. They describe it as a proof-of-concept, exploratory clinical trial. It enrolled 58 healthy, active adults (33 women, average age 35.5 years). For six weeks, participants took one of three regimens:
- Placebo: maltodextrin, 2 × 6 g per day
- GAA: 2 × 1 g per day (2 g total) plus a 2 × 5 g placebo
- GAA + creatine monohydrate: 2 g GAA plus 2 × 5 g CrM per day (10 g total)
Before and after supplementation, participants gave fasting blood samples and completed cognitive tests and questionnaires on mood, stress, sleep, and quality of life. The trial was registered as ISRCTN68542582.
The Striking Finding: Faster Reaction Times
The most eye-catching result came from reaction time. GAA alone tended to improve overall reaction time by about 242 ms, but the confidence interval crossed zero (-533 to 50 ms, p = 0.10). Statistically, that is a trend and not a confirmed effect.
The interaction analyses, which compare how groups changed over time against placebo, were stronger. They showed a significant effect on overall reaction time (about -330 ms, p = 0.031) and on "YES" reaction time (about -290 ms, p = 0.004). Two related measures, recalled-correct reaction time and recalled-correct YES accuracy, only approached significance (p = 0.078 and p = 0.084). The authors' conclusion describes improvements in delayed verbal episodic recognition memory and retrieval speed.
The Catch: Most Tests Showed Nothing
The cognitive picture was far less impressive elsewhere. The abstract reports limited to no effects on the Delayed Picture Recognition Task, Digit Vigilance Task, Corsi Block Task, and Stroop Color-Word Task. Those tests cover visual memory, sustained attention, spatial working memory, and executive control. The authors also admit to inconsistencies in their findings, especially when GAA was compared directly with placebo. So the supplement did not lift cognition across the board. At best it nudged one cluster of speed-related measures.
Mood, Stress, Sleep, and Quality of Life
The secondary outcomes were a mixed bag, and many sat in the "approaching significance" zone (p between 0.05 and 0.10):
- Physical activity: The GAA group reported significantly more time in moderate physical activity than placebo.
- Stress: The GAA group reported a lower frequency of controlling irritations (p = 0.036) and of feeling that difficulties were mounting (p = 0.053) on the Perceived Stress Scale. The authors counted these among the stress improvements. The abstract doesn't spell out how the items were scored, so read that first item cautiously until the full paper is checked.
- Sleep: The abstract says there were "some positive and potentially undesirable effects" on sleep quality, without detail.
- Quality of life: The GAA group felt less worn out (p = 0.068) and rated their health as excellent more often (p = 0.092). The GAA + CrM group reported more frequent limitations bending, kneeling, or stooping (p = 0.053), but also felt more full of life (p = 0.081) and less downhearted and depressed (p = 0.066).
A wide net of questionnaires almost guarantees a few lucky hits. None of these secondary findings should be treated as established.
Safety Check
On safety, the trial gave no cause for alarm. The researchers saw no clinically meaningful changes in blood markers and no meaningful differences in self-reported side effects among the groups over six weeks.
Limitations and Conflicts to Know About
This was a small, exploratory study. With 58 people split across three conditions, it had limited power, and the many outcomes measured raise the risk of false positives. Several key results were only trends. The participants were healthy and active, so the results may not apply to people with cognitive complaints, older adults, or clinical populations. The trial lasted only six weeks.
On funding, the sponsor was the WoodNext Foundation, which does not sell nutrition or creatine products. Senior author Richard Kreider has long researched creatine and serves as a paid consultant to the Scientific Advisory Board chair at AlzChem, a company that makes both creatine monohydrate and GAA. The paper discloses that relationship, and the authors say the university reviews these roles. It is still context worth knowing.
Practical Takeaways
- Dose studied: 2 g/day of GAA (split into two 1 g servings), alone or with 10 g/day of creatine monohydrate (two 5 g servings), for six weeks. The abstract gives no other timing guidance.
- Who might be curious: Healthy, active adults who want to experiment, ideally knowing the evidence is preliminary.
- Who should skip it or ask a doctor first: The abstract reports no data on children, pregnant or breastfeeding women, older adults, or people with kidney or other medical conditions, so there is no evidence for those groups. Anyone on medication or with a health condition should check with a clinician.
- Expectation setting: Don't expect a broad cognitive upgrade. The data point to possible gains in reaction speed and some subjective wellbeing measures, not sharper memory or focus across the board.
- Cheaper alternative: This trial can't say whether GAA beats plain creatine monohydrate for cognition, because it had no creatine-only arm. The GAA + CrM group makes it impossible to separate each compound's contribution.
The Verdict
GAA has not been shown to be a proven brain booster. The study shows a plausible signal in reaction time, a clean short-term safety profile, and a scattering of mood and quality-of-life hints. It also shows that most cognitive tests did not budge. As the authors put it, more research is needed before conclusions can be drawn. For now, GAA is an interesting hypothesis rather than a proven upgrade.
